Welcome to the latest issue of Blockbuster Biologics Review, which covers the status and developments of post-grant challenges and patent ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands ...

Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

It’s no secret that prescription drugs can take a toll on your wallet. One classification of medication in particular—biologics—has had an oversized impact on the rising cost of prescription drugs.

The biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 8.8% during the projected period. The ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs; The agreement includes pr ...

There's a need for early anti-tumor necrosis factor (TNF) therapy in inflammatory bowel disease (IBD), with new data showing ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

NEW JERSEY, NJ, UNITED STATES, May 26, 2025 /EINPresswire.com/ -- The global biosimilars market is experiencing robust growth as healthcare systems strive to improve patient access to life-saving ...